StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Significant revenue and earnings beats indicate strong operational performance. Positive guidance revisions suggest robust future growth.
What happened, with direct paths to the underlying reporting
CRMD reported Q3 earnings of $1.26, beating estimates significantly. Sales surged to $104.27 million, up from $11.5 million last year. Full-year 2025 revenue guidance raised to $390-$410 million from $283.69 million. DefenCath utilization drove $88.8 million in revenue this quarter. CRMD stock increased 12.06% following the earnings report.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.